GlassScriptPhysician profile
Abdul Hamid Alraiyes
NPI 1861626731
$76,166.45
in general payments reported to CMS, 2019-2025
23 companies · $7,040 in 2025
The $7,040 reported for 2025 was more than what 91% of Pulmonary Disease providers received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $8,321 · 2020: $113 · 2021: $5,507 · 2022: $23K · 2023: $25K · 2024: $6,718 · 2025: $7,040.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Education: $26K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $5,770 · Food and Beverage: $3,186 · Consulting Fee: $2,250 · Travel and Lodging: $1,697.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Education | $26,000.00 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $5,770.00 |
| Food and Beverage | $3,186.00 |
| Consulting Fee | $2,250.00 |
| Travel and Lodging | $1,697.03 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $64,679.13 | 2019-2025 | Da Vinci Surgical System, Da Vinci Sp |
| Covidien LP | $4,853.22 | 2019 | |
| Pulmonx Corporation | $2,876.78 | 2021-2024 | Zephyr Endobronchial Valve, Chartis Catheter, Pulmonx Chartis Tablet Console |
| Medtronic, INC. | $789.89 | 2023-2024 | Illumisite |
| Astrazeneca Pharmaceuticals LP | $751.08 | 2019-2024 | |
| Noah Medical Corporation | $571.39 | 2023 | |
| Ethicon INC. | $517.02 | 2019 | |
| Pinnacle Biologics, INC | $287.15 | 2019-2025 | Photofrin |
| Boston Scientific Corporation | $221.35 | 2023-2024 | Acquire |
| Amgen INC. | $128.68 | 2019-2020 | |
| Siemens Medical Solutions USA, INC. | $119.76 | 2023 | Cios Spin |
| Olympus America INC. | $80.83 | 2022 | |
| Cook Medical LLC | $60.49 | 2023 | Cook |
| Regeneron Healthcare Solutions, INC. | $49.66 | 2019 | |
| Olympus Corporation of The Americas | $25.76 | 2019 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Taiho Oncology, INC. | $23.70 | 2019 | |
| Astellas Pharma US INC | $21.27 | 2019 | |
| Coherus Oncology, INC. | $20.33 | 2020 | |
| Merck Sharp & Dohme LLC | $19.65 | 2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $18.89 | 2019 | |
| Cumberland Pharmaceuticals, INC. | $17.90 | 2019 | |
| Pfizer INC. | $16.75 | 2020 | |
| Novartis Pharmaceuticals Corporation | $15.77 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Abdul Hamid Alraiyes listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.